Osi-461 (Osi)
Galmarini, C.M.
Current Opinion in Investigational Drugs 5(6): 648-656
2004
ISSN/ISBN: 1472-4472 PMID: 15242254 Document Number: 583744
OSI Pharmaceuticals is developing OSI-461, a potent analog of exisulind, for the potential treatment of cancer and inflammatory bowel disease. In August 2001, OSI-461 entered phase II trials involving patients with chronic lymphocytic leukemia. In July 2002, the company embarked on a pilot phase II study evaluating OSI-461 for the treatment of Crohn's disease. By October 2002, Cell Pathways had selected hormone-refractory prostate cancer as the lead cancer indication for clinical development of OSI-461.